COST EFFECTIVENESS OF EVEROLIMUS FOR SECOND LINE TREATMENT OF METASTATIC RENAL CELL CANCER IN SERBIA

被引：0
|
作者：
Mihajlovic, J. [1 ]
Pechlivanoglou, P. [1 ]
Sabo, A. [2 ]
Tomic, Z. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Univ Novi Sad, Fac Med, Novi Sad 21000, Serbia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2141
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [31] Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma
    Alesini, Daniele
    Mosillo, Claudia
    Naso, Giuseppe
    Cortesi, Enrico
    Iacovelli, Roberto
    THERAPEUTIC ADVANCES IN UROLOGY, 2015, 7 (05) : 286 - 294
  • [32] BUDGET IMPACT ANALYSIS OF USING PAZOPANIB-EVEROLIMUS IN FIRST AND SECOND LINE OF TREATMENT, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Romero Prada, M. E.
    Celis, S.
    Acero, G.
    Huerfano, L. M.
    VALUE IN HEALTH, 2016, 19 (07) : A719 - A719
  • [33] Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study
    Rizzo, Mimma
    Facchini, Gaetano
    Savastano, Clementina
    Di Lorenzo, Giuseppe
    De Lucia, Luigi
    Maiorino, Luigi
    Casale, Beniamino
    Grimaldi, Giuseppe
    Formato, Roberta
    Febbraro, Antonio
    Carteni, Giacomo
    FUTURE ONCOLOGY, 2015, 11 (02) : 219 - 224
  • [34] Sequential treatment of metastatic Renal cell carcinoma Everolimus in Therapy of metastatic Renal cell carcinoma
    Gschwend, Juergen E.
    AKTUELLE UROLOGIE, 2011, 42 (03) : A4 - A5
  • [35] Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.
    Vogelzang, Nicholas J.
    Pal, Surnanta Kumar
    Signorovitch, James E.
    Reichmann, VVilliam M.
    Chopra, Pooja
    Liu, Zhimei
    Perez, Jose Ricardo
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [36] Does first-line treatment impact the cost-effectiveness of second-line treatment for elderly metastatic colon cancer patients?
    Mullins, C. Daniel
    Woldemichael, Andinet
    Zheng, Zhiyuan
    Onukwugha, Ebere
    Seal, Brian S.
    Hanna, Nader
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [37] Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
    Zheng, Huanrui
    Zhou, Jin
    Tong, Yao
    Zhang, Jinhua
    CLINICAL GENITOURINARY CANCER, 2025, 23 (01)
  • [38] COST-EFFECTIVENESS OF PAZOPANIB AS FIRST LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN BRAZIL: UPDATED ANALYSIS
    Pepe, C.
    Sedlmayer, C.
    Machado, M.
    VALUE IN HEALTH, 2013, 16 (07) : A685 - A685
  • [39] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma
    Benton, John Z.
    Klaassen, Zachary
    Wallis, Christopher J. D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (02) : 285 - 286
12345